CD38+CD27-TNF-α + on Mtb-specific CD4+ T Cells Is a Robust Biomarker for Tuberculosis Diagnosis
- PMID: 34492697
- DOI: 10.1093/cid/ciab144
CD38+CD27-TNF-α + on Mtb-specific CD4+ T Cells Is a Robust Biomarker for Tuberculosis Diagnosis
Abstract
Background: Early and accurate diagnosis followed by timely treatment are the key prerequisites to fight tuberculosis (TB) and reduce its global burden. Despite scientific advances, the rapid and correct diagnosis of both pulmonary and extrapulmonary tuberculosis remains a challenge because of traditional reliance on detection of the elusive bacilli. Mycobacterium tuberculosis (Mtb)-specific host immune activation and cytokine production have shown significant promise as alternative means of detecting and distinguishing active disease from latent infection. We queried the diagnostic ability of phenotypic markers on Mtb-specific cytokine-producing immune cell subsets for identifying active TB.
Methods: Subjects belonging to the following groups were recruited: pulmonary and extrapulmonary TB, latent TB, cured TB, sick controls, and healthy controls. Polychromatic flow cytometry was used to identify host immune biomarkers in an exploratory cohort comprising 56 subjects using peripheral blood mononuclear cells. Clinical performance of the identified biomarker was evaluated using whole blood in a blinded validation cohort comprising 165 individuals.
Results: Cytokine secreting frequencies of Mtb-specific cluster of differentiation 4-positive (CD4+) T cells with CD38+CD27- phenotype clearly distinguished infected individuals with active tuberculosis from those without disease. Tumor necrosis factor-α (TNF-α) secretion from CD38+CD27-CD4+ T cells upon stimulation with ESAT6/CFP10 peptides had the best diagnostic accuracy at a cutoff of 9.91% (exploratory: 96.67% specificity, 88.46% sensitivity; validation: 96.15% specificity, 90.16% sensitivity). Additionally, this subset differentiated treatment-naive patients with TB from individuals cured of TB following completion of anti-TB therapy.
Conclusions: Mtb-specific CD38+CD27-TNF-α +CD4+ T-cell subset is a robust biomarker both for diagnosing TB and assessing cure.
Keywords: TNF-α; biomarker; diagnosis; flow cytometry; tuberculosis.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Similar articles
-
Study of CD27 and CCR4 Markers on Specific CD4+ T-Cells as Immune Tools for Active and Latent Tuberculosis Management.Front Immunol. 2019 Jan 9;9:3094. doi: 10.3389/fimmu.2018.03094. eCollection 2018. Front Immunol. 2019. PMID: 30687314 Free PMC article.
-
Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy.Front Immunol. 2018 Sep 28;9:2247. doi: 10.3389/fimmu.2018.02247. eCollection 2018. Front Immunol. 2018. PMID: 30323818 Free PMC article.
-
Distinct effector memory CD4+ T cell signatures in latent Mycobacterium tuberculosis infection, BCG vaccination and clinically resolved tuberculosis.PLoS One. 2012;7(4):e36046. doi: 10.1371/journal.pone.0036046. Epub 2012 Apr 24. PLoS One. 2012. PMID: 22545156 Free PMC article.
-
Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis.Front Immunol. 2014 Apr 22;5:180. doi: 10.3389/fimmu.2014.00180. eCollection 2014. Front Immunol. 2014. PMID: 24795723 Free PMC article. Review.
-
[Evolution of IGRA researches].Kekkaku. 2008 Sep;83(9):641-52. Kekkaku. 2008. PMID: 18979999 Review. Japanese.
Cited by
-
Integrated bioinformatic analyses investigate macrophage-M1-related biomarkers and tuberculosis therapeutic drugs.Front Genet. 2023 Feb 8;14:1041892. doi: 10.3389/fgene.2023.1041892. eCollection 2023. Front Genet. 2023. PMID: 36845395 Free PMC article.
-
Combination of HLA-DR on Mycobacterium tuberculosis-Specific Cells and Tuberculosis Antigen/Phytohemagglutinin Ratio for Discriminating Active Tuberculosis From Latent Tuberculosis Infection.Front Immunol. 2021 Nov 11;12:761209. doi: 10.3389/fimmu.2021.761209. eCollection 2021. Front Immunol. 2021. PMID: 34858413 Free PMC article.
-
Active tuberculosis patients have high systemic IgG levels and B-cell fingerprinting, characterized by a reduced capacity to produce IFN-γ or IL-10 as a response to M.tb antigens.Front Immunol. 2023 Oct 26;14:1263458. doi: 10.3389/fimmu.2023.1263458. eCollection 2023. Front Immunol. 2023. PMID: 38022616 Free PMC article.
-
Mycobacterium tuberculosis antigen-specific T-cell responses in smear-negative pulmonary tuberculosis patients.Clin Exp Immunol. 2022 Jul 22;209(1):99-108. doi: 10.1093/cei/uxac049. Clin Exp Immunol. 2022. PMID: 35552657 Free PMC article.
-
Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control Strategy.Front Microbiol. 2021 Oct 22;12:745592. doi: 10.3389/fmicb.2021.745592. eCollection 2021. Front Microbiol. 2021. PMID: 34745048 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials